🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

242 results for “ANI” Clear

  1. Delamanid, Bedaquiline, OPC-167832, and Sutezolid (DBOS)

    BRIGHT MINDS BIOSCIENCES INC.

    Pulmonary Tuberculosis

    phase 2 small molecule terminated

    1 trial

  2. Etoposide 20 mg/ml Concentrate for solution for infusion , KEYTRUDA 25 mg/mL concentrate for solution for infusion, Cisplatine Teva 1 mg/ml solution à diluer pour perfusion., ADRIBLASTINE 10 mg, poudre pour solution injectable en flacon, Cyclophosphamide Sandoz, 100 mg/mL, koncentrat do sporządzania roztworu do wstrzykiwań / do infuzji

    Cancer Prevention Pharma (Ireland) Limited

    Patients with a confirmed diagnosis of ovarian small cell carcinoma.

    phase 2 small molecule active

    1 trial

  3. FGF-2

    United Therapeutics Europe Ltd

    Tympanic Membrane Perforation

    phase 2 small molecule completed

    1 trial

  4. FOLINIC ACID, FLUOROURACIL, BEVACIZUMAB, Telisotuzumab adizutecan, FOLINIC ACID, PANITUMUMAB, OXALIPLATIN

    AbbVie Deutschland GmbH & Co. KG

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  5. Film-coated tablet, Major Ingredients Mannitol, microcrystalline cellulose, magnesium stearate, polyvinyl alcohol, macrogol, titanium dioxide and talc, Fipaxalparant

    Elan Pharma International

    Diffuse Cutaneous Systemic Sclerosis

    phase 2 small molecule active

    1 trial

  6. Fipaxalparant, Film-coated tablet, Major Ingredients Mannitol, microcrystalline cellulose, magnesium stearate, polyvinyl alcohol, macrogol, titanium dioxide and talc

    Elan Pharma International

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule active

    1 trial

  7. Fluocinolone Acetonide

    ANI PHARMACEUTICALS INC

    Macular Edema

    phase 2 small molecule terminated

    1 trial

  8. Fluocinolone Acetonide

    ANI PHARMACEUTICALS INC

    Age-Related Macular Degeneration

    phase 2 small molecule terminated

    1 trial

  9. GRANISETRON EXTENDED RELEASE INJECTION (GERSC)

    Heron Therapeutics

    Chemotherapy-induced Nausea and Vomiting

    phase 2 small molecule terminated

    1 trial

  10. Galinpepimut-S + Montanide + GM-CSF

    United Therapeutics Europe Ltd

    Malignant Pleural Mesothelioma

    phase 2 mab completed

    1 trial

  11. Humanized CD7 CAR-T cells

    First Tracks Biotherapeutics

    T Lymphoblastic Leukemia/Lymphoma

    phase 2 mab active

    1 trial

  12. Humanized IgG1 monoclonal antibody against GD2, Leukine

    Y-Mabs Therapeutics A/S

    Treatment of high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow

    phase 2 small molecule active

    1 trial

  13. Humanized anti-CD117 Monoclonal Antibody (JSP191)

    Jasper Therapeutics

    SCID

    phase 2 mab terminated

    1 trial

  14. Humanized immunoglobulin G1 (IgG1) kappa monoclonal antibody (mAb) targeting PAUF

    Pharma Mar S.A.

    Advanced and/or metastatic pancreatic adenocarcinoma

    phase 2 small molecule active

    1 trial

  15. IFOSFAMIDE, CISPLATIN, PACLITAXEL, METHYLPREDNISOLONE, RANITIDINE, MESNA, APREPITANT, DEXCHLORPHENIRAMINE MALEATE

    Cancer Prevention Pharma (Ireland) Limited

    Penis carcinoma

    phase 2 small molecule active

    1 trial

  16. INDOCYANINE GREEN

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Patients with primary invasive early breast cancer (T1-T2) that will undergo planned breast-conserving surgery

    phase 2 small molecule active

    1 trial

  17. INDOCYANINE GREEN

    Fondazione Telethon ETS

    Patients with gynecological cancers undergoing pelvic exenteration

    phase 2 small molecule active

    1 trial

  18. IOBENGUANE (123I) , [18F]meta-fluorobenzylguanidine

    AXIM BIOTECHNOLOGIES, INC.

    (suspision on) Neuroblastoma

    phase 2 small molecule active

    1 trial

  19. Injection of humanized nerve growth factor (NGF) antibody

    Sunshine Biopharma

    Cancer Pain

    phase 2 small molecule active

    1 trial

  20. La composición cualitativa y cuantitativa de cada sobre de placebo es la siguiente: Bicarbonato sódico 563,75 mg Diluyente/generador de efervescencia Ph Eur Ácido cítrico 410,0 mg Diluyente/generador de efervescencia Ph Eur Maltodextrina 651,25 mg Diluyente Ph Eur Sílice coloidal anhidra 10,0 mg Fluidificante/desecante interno Ph Eur Manitol 769,0 mg Diluyente Ph Eur Sacarina sódica 24,0 mg Edulcorante Ph Eur Aroma de naranja 72,0 mg Saborizante Espec.. interna Masa nominal 2.500 mg El polvo efervescente se

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Amyotrophic Lateral Sclerosis (ALS)

    phase 2 small molecule active

    1 trial

  21. Matched Placebo

    Novo mesto

    Mechanical allodynia

    phase 2 small molecule active

    1 trial

  22. MenQuadfi solution for injection Meningococcal Group A, C, W and Y conjugate vaccine, DANICOPAN, Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNA, component, adsorbed)

    Pharma Mar S.A.

    Chronic spontaneous urticaria

    phase 2 small molecule active

    1 trial

  23. NaCl 0.9%, GAMMA-OH 200 mg/ml, solution injectable (IV)

    Pari Pharma GmbH

    The study population includes adult ICU patients with a hospitalization of more than 48 hours. We have chosen to include patients with or without mechanical ventilation, as sleep disorders affect all ICU patients after 48 hours.

    phase 2 small molecule active

    1 trial

  24. Nintedanib,Dextromethorphan

    First Tracks Biotherapeutics

    Idiopathic Pulmonary Fibrosis (IPF)

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources